Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

rnal of Neuroscience (Vol 27, pp.294-

300, 2008).

- The results from the phase III ACCLAIM trial of our Celacade System

in patients with chronic heart failure were published in the

January 19th issue of The Lancet (Lancet 2008; 371: 228-36), a world-

leading medical journal. As we previously reported, while the trial

did not meet its primary endpoint, a key finding from the ACCLAIM

trial was a 39% reduction in the risk of death or cardiovascular

hospitalizations for a large pre-specified subgroup of patients with

NYHA Class II heart failure who received Celacade therapy, compared

to patients receiving placebo.

- On March 14, 2008, we had a teleconference with the FDA to discuss

and clarify the recent comments from the agency regarding the use of

a Bayesian approach for ACCLAIM II, a clinical trial which is being

planned to support an application for U.S. market approval of the

Celacade System for the treatment of patients with New York Heart

Association ("NYHA") Class II heart failure. The teleconference with

the FDA follows our announcement on March 3rd, stating that the FDA

disagrees with the use of a Bayesian approach for the planned ACCLAIM

II study. This is contrary to the FDA's original communication to us

recommending a Bayesian study design. We have prepared and submitted

a written response to the FDA's comments with respect to the use of a

Bayesian approach in ACCLAIM II.

- Grupo Ferrer Internacional, S.A. ("Ferrer"), our European marketing

partner, has the right to market Celacade for the treatment of

chronic heart failure in certain countries of the European Union

("E.U.") and Latin America. Celacade has already received E.U.

regulatory approval as a medical device under the CE Mark, which


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Cmed Technology , an eClinical ... and give a presentation about electronic data capture (EDC) ... Ops Executives ( SCOPE ) conference at Florida,s Westin ... As part of SCOPE,s two-day "Electronic Data In ...
... Ky., Feb. 4, 2011 MediVet-America, the leading ... animals suffering from osteoarthritis, hip dysplasia, ligament and ... year of business having achieved record advances in ... Adipose-Derived Stem Cell Procedure Kit and equipment, veterinary ...
... (Pink Sheets: AVXT ) ("AVAX" or the ... with the Securities and Exchange Commission ("SEC").  Upon the ... become a publicly reporting company.  The Company intends to ... Over-the-Counter Bulletin Board.  The Company,s Form 10, which contains ...
Cached Biology Technology:Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year 2AVAX Technologies, Inc. Files Form 10 With SEC 2
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
(Date:7/9/2014)... research has uncovered how a complex protein pivotal in ... is activated. The discovery answers a key question about ... which has been the subject of tens of thousands ... funding. , Jiazhen Zhang, a research student in Professor ... uncovered how the protein complex, called NF-κB, is activated. ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
Breaking Biology News(10 mins):Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3Research reveals how key controller protein is switched on 2UC Riverside plant pathologist receives national recognition 2
... in a jetliner act and feel one way when crammed ... a different mindset when the middle seat is empty and ... parallel that exists among the proteins involved in health and ... issue of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
... Georges Belfort has been recognized for his fundamental ... engineering. Belfort, the Russell Sage Professor of ... weeks received the 2011 Alan S. Michaels Award ... American Chemical Society (ACS) Biotechnology Division. ...
... A fascinating study published in the BMJ shows ... each week, as they drink daily, rather than more on ... disease than the Northern Irish. Ruidavets and colleagues compared groups ... have very different drinking cultures and rates of heart disease.The ...
Cached Biology News:Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2Pattern of drinking affects the relation of alcohol intake to coronary heart disease 2
...
Alexa Fluor 647 anti-mouse Qa-2...
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
... The Luminex 100 Instrument System ... multi-analyte assays using Upstate's Beadlyte reagents. ... the Dell computer with software version ... Sheath Delivery System. Upstate offers $2000 ...
Biology Products: